抗耐甲氧西林金黄色葡萄球菌的抗感染药物。
Anti-infectious agents against MRSA.
机构信息
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
出版信息
Molecules. 2012 Dec 24;18(1):204-24. doi: 10.3390/molecules18010204.
Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described.
临床上有用的抗生素，如β-内酰胺类和万古霉素，已知能抑制细菌细胞壁肽聚糖的合成。耐甲氧西林金黄色葡萄球菌（MRSA）具有独特的细胞壁结构，由肽聚糖和壁磷壁酸组成。近年来，采用独特的筛选方法发现了针对 MRSA 细胞壁生物合成的新型抗感染药物（螺恶嗪、三丙肽 C、DMPI、CDFI、cyslabdan、1835F03 和 BPH-652）。这些药物被发现能抑制细胞壁生物合成中涉及的重要酶，如十一烯基焦磷酸（UPP）合酶、FemA、翻转酶或 UPP 磷酸酶。在这篇综述中，描述了这些抗感染药物的发现、作用机制和未来前景。
Zotero 插件